Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The HORIZON-GEA-01 trial's control arm used a standard of care (trastuzumab + chemo) that was superseded in the US by the addition of pembrolizumab during the trial. This design was appropriate at launch but creates a slight disconnect with current US practice, requiring clinicians to interpret results in a new context.
Related Insights
The Destiny Breast 11 trial compared a new drug to a chemotherapy regimen (ACTHP) that many US oncologists no longer use. This choice of a less common control arm makes it difficult for them to directly compare the new treatment's efficacy against their own current standard (TCHP), complicating adoption.
The apparent lack of survival benefit for datopotamab in North American patients is likely an artifact. Better access to other effective antibody-drug conjugates after progression in the control arm diluted the survival advantage, highlighting how regional care standards can confound trial outcomes.
The Sac o six nineteen trial showed compelling results adding BCG to a chemo-immunotherapy backbone. However, the standard of care has already shifted to a newer combination (enfortumab vedotin and pembrolizumab), making it difficult to translate the study's findings into current practice and complicating the design of future trials.
The LIDERA trial's success is complicated because it was designed against a standard of care that is now outdated. It excluded CDK4/6 inhibitors, which are now common for high-risk patients, creating a gap in understanding how to integrate this new drug into modern clinical practice.
Clinicians identify outdated control arms—like single-agent chemotherapy without newer targeted agents—as a major deterrent for patient trial participation. Patients are unwilling to be randomized to a therapy that doesn't reflect the current, more effective standard of care. This pressure is forcing sponsors and the FDA to design trials with more realistic comparator arms.
Pirtobrutinib's registrational trials used control arms (ibrutinib, bendamustine-rituximab) that are no longer the standard of care in the US. This strategy reflects the long timeline of trial design and the need to use comparators that are still considered a standard globally, ensuring broader regulatory acceptance and allowing for cross-trial comparisons.
The high rate of grade 3 diarrhea seen in the Zanidatamab trial was likely exacerbated by the capecitabine-based chemotherapy common in the global study. US oncologists, who often prefer a Folfox regimen, may see less severe GI toxicity, potentially improving patient tolerance and adherence to this highly effective regimen.
The pace of new drug approvals in oncology means that established clinical trial control arms, often using older chemotherapies, may no longer represent the true standard of care. This discrepancy can deter patient enrollment and challenges trial designers to remain nimble and current.
The Horizon GA-01 trial's control arm became outdated mid-study when a superior standard of care (Keynote 811) was approved. This highlights a critical challenge in drug development: long trial timelines can conflict with rapid progress, making it difficult to compare new agents against the true contemporary standard.
Unlike trastuzumab, zanidatumab's effectiveness in the HORIZON-GEA-01 trial did not seem to depend on PD-L1 status. This surprising finding suggests a novel, possibly immune-mediated, mechanism of action that could expand its use to a broader patient population, including those who are PD-L1 negative.
